Seres Therapeutics (NASDAQ:MCRB) Stock Price Crosses Below 200 Day Moving Average – Here’s What Happened

Seres Therapeutics, Inc. (NASDAQ:MCRB)’s share price crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $14.41 and traded as low as $7.14. Seres Therapeutics shares last traded at $7.46, with a volume of 76,902 shares trading hands.

Analyst Upgrades and Downgrades

Several equities analysts have commented on MCRB shares. StockNews.com upgraded Seres Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, May 9th. Chardan Capital reiterated a “neutral” rating and issued a $6.00 target price (up from $1.25) on shares of Seres Therapeutics in a research report on Thursday, May 8th. Finally, The Goldman Sachs Group lowered their price objective on Seres Therapeutics from $20.00 to $15.00 and set a “sell” rating for the company in a research report on Friday, March 14th. Two analysts have rated the stock with a sell rating, three have given a hold rating and one has given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $73.67.

Seres Therapeutics Stock Up 0.7%

The firm has a 50 day moving average of $10.93 and a 200 day moving average of $14.40. The firm has a market cap of $65.14 million, a price-to-earnings ratio of -32.43 and a beta of 2.89.

Seres Therapeutics (NASDAQ:MCRB) last released its earnings results on Wednesday, May 7th. The biotechnology company reported ($2.24) EPS for the quarter, missing the consensus estimate of ($0.67) by ($1.57). Equities analysts expect that Seres Therapeutics, Inc. will post -0.38 EPS for the current year.

Institutional Trading of Seres Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Millennium Management LLC raised its stake in shares of Seres Therapeutics by 77.2% during the 4th quarter. Millennium Management LLC now owns 1,810,719 shares of the biotechnology company’s stock valued at $1,505,000 after purchasing an additional 788,762 shares during the period. Geode Capital Management LLC raised its stake in shares of Seres Therapeutics by 8.8% during the 4th quarter. Geode Capital Management LLC now owns 1,510,432 shares of the biotechnology company’s stock valued at $1,256,000 after purchasing an additional 121,793 shares during the period. Vontobel Holding Ltd. raised its stake in shares of Seres Therapeutics by 15.7% during the 1st quarter. Vontobel Holding Ltd. now owns 1,085,966 shares of the biotechnology company’s stock valued at $760,000 after purchasing an additional 147,671 shares during the period. Charles Schwab Investment Management Inc. raised its stake in shares of Seres Therapeutics by 15.6% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 865,825 shares of the biotechnology company’s stock valued at $720,000 after purchasing an additional 117,107 shares during the period. Finally, Northern Trust Corp grew its position in Seres Therapeutics by 20.4% during the fourth quarter. Northern Trust Corp now owns 262,683 shares of the biotechnology company’s stock worth $218,000 after buying an additional 44,461 shares in the last quarter. 59.34% of the stock is currently owned by institutional investors.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.